Institutional Alpha Dossier
Loading Alpha Data...
MAINBOARD
SYNCING
GMP: ₹-
Est. Listing: Calculating...
01
Bidding Opens
-
Issue Open
02
Bidding Closes
-
Closing Date
03
Basis of Allotment
-
Registrar Finalization
04
Exchange Listing
-
Secondary Debut
Issue Price Valuation
₹-
Upper Cap Price
Price Band Cap:
Book Built / Fixed
Lot Size & Retail Matrix
- Shares
Minimum Market Lot
Min Capital:
₹-
Application Size:
-
Quant Grade & Moat Score
Proprietary Multi-Factor Moat Model
Synthesizing institutional thesis...
💼 MINIMUM INVESTMENT
Capital Matrix
Retail (Min Lot)
Up to ₹2 Lakhs Category
₹14820
HNI (Min Lot)
sNII / High Net-Worth Tier
₹207480
HNI Capital Multiple:
Institutional Lot Sizing
🍩 RESERVATION QUOTA (%)
Issue Allocation
100%
Total Issue
Anchor
29.95%
Market Maker
0%
QIB
19.97%
NII / HNI
14.97%
Retail
34.94%
Institutional Corporate Dossier
Symbiotec Pharmalab
COMPANY PROFILE & DNA
Incorporation / Founded
20-09-02
Active Vintage
Corporate Headquarters
Indore, Madhya Pradesh
Registered Hub
👔 Leadership & Promoter Group
Key Management
Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP
⚙️ Business Overview & Portfolio
Core Offerings
Developer, manufacturer and exporter of active pharmaceutical ingredients and intermediates.
🎯 Target Market & End-Use
Revenue Drivers
Universally applied in critical care setups and chronic therapeutic areas.
🛡️
★ Unique Selling Proposition (Core Economic Moat)
Global leadership in corticosteroid and steroidal hormone APIs with vertically integrated farm-to-pharmacy platform.
Objects of the Issue (Use of Proceeds & Allocation)
🎯 Objective 01
Prepayment and/or repayment of outstanding borrowings availed by our Company
₹112.50
Allocation
🎯 Objective 02
General corporate purposes
Balance
Allocation
🎯 Objective 03
Not Mentioned
₹0.00
Allocation
🎯 Objective 04
Not Mentioned
₹0.00
Allocation
Financial Performance & Multi-Year Trajectory
All Figures in ₹ Crores
Latest Total Income📊
₹-
Top-Line
EBITDA Margin⚡
-%
Operating
Net Profit (PAT) Margin📈
-%
Bottom-Line
Debt / Net Worth🛡️
-x
Leverage
📊 Income, EBITDA & Profit Growth Trajectory
Income
EBITDA
PAT Trend
🏛️ Balance Sheet: Net Worth vs Debt
Net Worth
Borrowing
| Particulars | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Total Income | 869.15 | 751.55 | 716.25 | 0.00 |
| EBITDA | 178.69 | 163.01 | 138.22 | 0.00 |
| Profit After Tax (PAT) | 109.90 | 96.78 | 100.05 | 0.00 |
| Net Worth | 1158.64 | 821.15 | 720.68 | 621.44 |
| Total Borrowing | 387.91 | 540.92 | 247.21 | 217.88 |
Growth Engine & Compounding Velocity (KPIs)
Multi-Year Trajectory
751.55
₹ Cr
YoY Growth
4.93%
3-Year CAGR
10.16%
163.01
₹ Cr
YoY Growth
17.94%
3-Year CAGR
13.70%
96.78
₹ Cr
YoY Growth
-3.27%
3-Year CAGR
4.81%
Capital Efficiency & Return Ratios (ROE vs ROCE)
Capital Allocation Audit
◈ ROE (Return on Equity)
Calculating...
-%
Current ROE
◈ ROCE (Capital Employed)
Calculating...
-%
Current ROCE
| MetricMetric | Current (%)Curr% | Last Year (%)Last% | 3-Yr Avg (%)3Y Avg | Trend StatusTrend |
|---|---|---|---|---|
| ROE (Return on Equity)ROE | 11.79% | 13.88% | 11.72% | Stable |
| ROCE (Capital Employed)ROCE | 11.97% | 14.28% | 12.60% | Stable |
Forensic Analysis & Reality Check
Earnings Quality & Dilution Audit
0.23
CFO / EBITDA
Cash Flow Conversion Efficiency
Checking...
Analyzing operating cash flow conversion...
| Parameter | Pre-IPO | Post-IPO | View |
|---|---|---|---|
| Debt / Equity | 0.66 | 0.28 | Low |
| EPS (₹) | ₹15.06 | ₹17.10 | Accretive |
| ROE (%) | 11.79% | 9.97% | Bad |
| ROCE (%) | 11.97% | 11.99% | Bad |
| P/E (Valuation) | 65.59 | 57.76 | Reasonable |
⏳ Debtor Days Trend (Receivables Cycle)
Analyzing...
FY23
FY24
FY25
Lower receivable days indicate faster cash collection from clients.
⚠️ Contingent Liabilities
Off-Balance Sheet
₹ 0.00 Cr
*Potential hidden obligations & legal/tax claims
Peer Comparison Analysis & Competitive Matrix
Industry Benchmarking
| Company NameComp | Revenue (Cr)Rev | P/E RatioP/E | ROCE (%)ROCE | ROE (%)ROE | OPM (%)OPM |
|---|---|---|---|---|---|
| Symbiotec Pharmalab Limited IPO CANDIDATE | 751.55 | 57.76 (Ask) | 11.97% | 9.97% (Post Issue) | 21.69% |
| Concord Biotech Limited | ₹1054.90 Cr | 61.07 | 0.17 | 14.00% | 0.348 |
| Divi's Laboratories Limited | ₹10560.00 Cr | 87.8 | 0.2123 | 16.50% | 0.36 |
| Cohance Lifesciences Limited | ₹2268.55 Cr | 95.02 | 0.108 | 7.00% | 0.19 |
| Laurus Labs Limited | ₹6812.90 Cr | 109.36 | 0.177 | 16.80% | 0.268 |
| 0 | 0 | 0 | 0 | 0.00% | 0 |
▲ Positive Catalysts (Strengths + Opportunities):
8 Factors
▼ Risk Vectors (Weaknesses + Threats):
8 Factors
Strengths
Internal Competitive Moat
- Global leadership in corticosteroid and steroidal hormone APIs
- Backward integrated farm to pharmacy manufacturing platform
- Long standing relationships with global customer base
- Strong in house research and development capabilities
Weaknesses
Internal Operational Constraints
- Substantial portion of revenue from select products
- Sourcing significant portion of raw materials from China
- Manufacturing facilities concentrated in Madhya Pradesh
- No long term contracts with key customers
Opportunities
External Growth Tailwinds
- Expanding biotechnology and CDMO service offerings
- Commercialization of complex injectables in regulated markets
- Diversifying into alternate proteins and nutraceuticals CDMO
- Penetrating high growth oncology and peptides market
Threats & Risks
External Macro & Sector Headwinds
- Intense competition from low cost API manufacturers
- Strict global regulatory compliance and safety standards
- Supply chain disruptions and intermediate import restrictions
- Volatility of raw material and utility prices
Top 10 Anchor Investors & Smart-Money Allocation
INSTITUTIONAL BOOK
Top 10 Anchor Commitment
₹- Cr
Smart-Money Quality Score
- / 5.0 ★
Marquee Conviction
SEBI Anchor Lock-In Schedule
30D (50%) • 90D (50%)
Mandatory Lock-In
Anchor Book Allocation Pending Exchange Filing
Institutional anchor investor bidding & allocation disclosures are officially filed with NSE/BSE 1 working day prior to the IPO opening date.
| Rank | Marquee Anchor Institution | Smart-Money Grade | Amount Invested | Anchor Share (%) |
|---|
1002
Strong moat due to global volume leadership in corticosteroid and steroidal hormone APIs, high entry barriers in specialized fermentation, and strong client stickiness (tenure >10 years), offset by high working capital (inventory turnover days >199 days).
29.95
0
QIB Quota
Qualified Institutional Buyers
Smart Money
-x
Institutional Book
Inst. Conviction:
Evaluating
NII / HNI Quota
sNII (₹2L-10L) & bNII (₹10L+)
HNI Desk
-x
Non-Institutional
HNI Competition Ratio:
-
Retail (RII) Quota
Individual Investors (Up to ₹2L)
SEBI Lottery
-x
Retail Book
Retail Allotment Odds:
-